Bio-Path (NASDAQ:BPTH) stock is rising higher on Friday alongside data from the oncology-focused company’s Phase 2 clinical trial of prexigebersen. Prexigebersen is Bio-Path product candidate for the targeted treatment of acute myeloid leukemia (AML) alongside decitabine and venetoclax. The big news is the company presented interim data from this study. Bio-Path says that its ongoing trial continues to show tolerance for the drug with few adverse events. The company is also starting to see compelling effici ...